Navigation Links
Concord Grape Juice Has No Significant Impact on Body Weight
Date:10/6/2008

Recent study revealed that drinking polyphenol-rich 100% Concord grape juice was not associated with changes in appetite, energy intake or body weight

CONCORD, Mass., Oct. 6 /PRNewswire/ -- Regular consumption of 100% polyphenol-rich Concord grape juice did not cause significant weight gain, was not associated with changes in appetite and was shown to reduce waist circumference according to new data presented at the 49th Annual Meeting of the American College of Nutrition in Arlington, Virginia(i).

The 12 week, double-blind, placebo-controlled trial examined the effect of regular consumption of 100% Concord grape juice on body weight, diet quality, and markers of metabolic syndrome. The study included 76 men and women between the ages of 18 and 50 years who were slightly overweight (body mass index of 25.0 to 29.9). Each participant drank two 8-ounce servings of 100% Concord grape juice per day (n=25), a polyphenol-free grape-flavored drink (n=26) or was assigned to a non-treatment control group (n=25). The two test beverages were calorie and sugar matched but only the 100% Concord grape juice contained natural polyphenolic compounds(i).

Participants in the polyphenol-rich 100% Concord grape juice arm did not show significant weight gain whereas participants who drank the placebo gained on average 1.6kg / 3.4lbs (p<0.05) compared to baseline. Those in the 100% Concord grape juice arm did not show a significant change in appetite, while those who drank the placebo showed a significant decline in self-reported fullness (p<0.005) over the same time period. Furthermore, participants in the 100% Concord grape juice arm exhibited a significant reduction in waist circumference, demonstrating a beneficial effect on one of the markers of metabolic syndrome. There were no changes in other markers of metabolic syndrome, including cholesterol, triglyceride, and fasting glucose levels which were all within normal limits throughout the study.

"P
'/>"/>

SOURCE Welch's
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
3. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
4. Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
5. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
6. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
7. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
8. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
9. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
10. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Call/--Hologic,Inc.(HologicortheCompany)(Nasdaq: H...remiumdiagnostics,medicalimagingsystemsandsurgical...n,isusingtheannualmeetingoftheRadiologicalSocietyo...ber29throughDecember3,2009tohighlightournewSecurVi...stationsoftware. ,, TheHologicSecurViewworkstat...
(Date:11/25/2009)...dsResearchGroup,Inc.releasedWave1ofits LaunchTren...yndicatedmarketresearchprojecttrackingthelaunchofC...oughthefirstsixmonthsofavailability.Eachwaveofther...rmatologistsandqualitativeinformationfromasubsetof...ouse,typicalpatienttypes,productperceptions,promot...
(Date:11/25/2009)...e/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAmeric...hatitreceivedtheEnvironmentalResponsibilityandSust...mmit,sponsoredbytheCaliforniaManufacturersandTechn...ssociation(IEA)andtheChemicalIndustryCouncilofCali...sawardavailablefromallthreeorganizationsandgainssu...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 1AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 2AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 3AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 4AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 5AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 6AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 7AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 8AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 9AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 10AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 11AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 12AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 13AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 14AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 15AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 16AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 17AMERIGROUP Reports Q3 Net Income of 2422 5 Million or 240 43 per Diluted Share 60386 18AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3
...reported in,the journal Pharmacogenomics suggests ...ic Factor gene (CNTF) may affect response to,antip...Pharmaceuticals,Inc., included patients with acute... with Fiapta(TM) (iloperidone), a novel atypical,a... FDA, or placebo.,Patients were also studied for a...
...r Blood-Derived Stem Cells and Strong In...NEW YORK, Feb. 28 NeoStem, Inc. (Amex: NBS ),whi...ssing and long-term,storage of adult stem cells fo...ositive research conclusions and industry trends p...sociation and at the recent Third Annual,Stem Cell...
Other Medicine Technology:Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 2Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 2NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 3NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit 4
(Date:11/25/2009)..., SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--...nterforDrugEvaluationandResearch,titled"ADifficult...rsintheNov.26,2009issueofTheNewEnglandJournalofMed.../prnh/20090824/FDALOGO ) ,, Inthearticle,Woodco...topainmedicationforthosewhoneeditandmanagingtheris...
(Date:11/25/2009)..., SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQu...inter Spare the Air Alert forThursda...firelogsoranyothersolidfuel,bothindoorsandoutdoors...yairqualitytomorrow,"saidJackBroadbent,executiveof...torespectthehealthoftheirneighborsandfellowcommuni...
(Date:11/25/2009)...-term survivors of testicular cancer who were trea...ere side effects, including neurological side effe...not treated with chemotherapy, according to a new ... of the National Cancer Institute . , Marianne B...nd University Hospital, in Bergen, Norway, and col...
(Date:11/25/2009)...fortuitous discovery that grew out of a collaborat...tentially offer hope to the nearly 10 million Amer... , Also known as hardening of the arteries, ...irculatory problem in which narrowed arteries redu...dered a red flag for vascular disease, heart attac...
(Date:11/25/2009)...udy follow-up period was too short to draw definit...AY, Nov. 25 (HealthDay News) -- In diabetic patien...o be no difference in outcomes at one year whether...th stenting, British researchers report. , Bypa...betic patients with coronary artery disease. Howev...
Breaking Medicine News(10 mins):Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3
...norrhea, one of the most common sexually transmitt...scientists say they are running // out of options ...ibe a group of commonly used antibiotics including...ion (CDC) says that the sexual disorder-that affec...
...rmaphrodites, commonly known as eunuchs, can now c...ive birth to babies - thanks //to a special proced...l Sciences (AIIMS) here. After proper diagnos...ier research and referral institute said. "T...
...Child abuse casts a shadow the length of a lifetim...tter Truth Little Sana was home alone, happ...while her mom eked out a living in a neighborhood .... He locked the door and raped her repeatedly. ...
...th allergy season in full bloom, the American Acad...ffering a reminder of what you can do to cope with...throat specialist can help. // This spring, p...s, nasal congestion and drainage, and sometimes he...
...ti-smoking campaigns highlighting the risk of resp... at women, according to a new study published in t...rofessor Robert Adams of the Queen Elizabeth Hospi...found hospital admissions and mortality from asthm...
...ctors should not shy away from writing letters of ... according to an article in the latest Medical Jou...igious society, some doctors may be wary of pennin... 'Letters can be dangerous in the hands of law...
Other Medicine News:Health News:Scientists Concerned About Gonorrhea’s Drug Resistanc 2Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2
Frazier
Ferguson-Frazier suction tube # 4
Ferguson-Frazier suction tube # 0
UltraLite® Plus Headlight System
Medicine Products: